Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity.
In the present work, we studied: (i) the effect of different doses of desferrioxamine and deferiprone on the proliferation of osteoblasts and the possible role of iron in this; and (ii) the effect of both chelators on the metabolic activity of these cells, using the quantification of alkaline phosphatase as an enzymatic marker of cellular activity or differentiation. Cellular proliferation was investigated at different concentrations of deferiprone and desferrioxamine, and the effect of the addition of iron citrate on this proliferation was measured. The production of alkaline phosphatase after incubation with deferiprone (150 and 300 microM) and desferrioxamine (20 and 100 microM) was also studied. Cellular proliferation was completely inhibited with 100 microM of desferrioxamine and 300 microM of deferiprone. In both cases, this effect was corrected by means of co-incubation with iron citrate. In the second phase, using the same dose that inhibited the proliferation, it was observed that after 24 h, both chelators slightly decreased alkaline phosphatase activity, while at 48 and 96 h they increased alkaline phosphatase activity. These results demonstrate that both desferrioxamine and deferiprone inhibit the proliferation of the osteoblast-like cell line MG-63; the effect seems to be related to the chelation of some fraction of available iron. In spite of the effect on bone cell proliferation, the chelators do not impair cellular activity.
Naves Díaz
M L
ML
Instituto Reina Sofía de Investigación Nefrológica, Hospital Central de Asturias, Departamento de Medicina, Universidad de Oviedo, Spain.
Elorriaga
R
R
Canteros
A
A
Cannata Andía
J B
JB
D000469:Alkaline Phosphatase / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D000077543:Deferiprone; D003676:Deferoxamine / Q000494:pharmacology*; D007501:Iron / Q000494:pharmacology; D007502:Iron Chelating Agents / Q000494:pharmacology*; D010006:Osteoblasts / Q000187:drug effects* / Q000502:physiology; D011728:Pyridones / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D000469:Alkaline Phosphatase; D003676:Deferoxamine